Therapeutic Response Statement (Sensitivity) Superseded

This therapeutic response statement Supports the relationship that dMMR status confers therapeutic sensitivity to Carboplatin, Dostarlimab, Paclitaxel in patients with Endometrial Carcinoma.

The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.

This statement is based on a regulatory approval from the European Medicines Agency:

JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.

Citation

GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2023-12-07	European Medicines Agency	Indication received approval from the European Commission.